Published in Respir Res on February 06, 2014
Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.03
Underrecognized comorbidities of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.95
Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review. PLoS One (2015) 0.83
Evaluation of the COPD Assessment Test and GOLD patient types: a cross-sectional analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.81
The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int J Chron Obstruct Pulmon Dis (2015) 0.81
Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients. Respir Res (2015) 0.79
The effect of comorbidities on COPD assessment: a pilot study. Int J Chron Obstruct Pulmon Dis (2015) 0.78
Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.77
The Role of Mitochondria and Oxidative/Antioxidative Imbalance in Pathobiology of Chronic Obstructive Pulmonary Disease. Oxid Med Cell Longev (2016) 0.76
Impact of mild exacerbation on COPD symptoms in a Japanese cohort. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Changes in exercise capacity, muscle strength, and health-related quality of life in esophageal cancer patients undergoing esophagectomy. BMC Sports Sci Med Rehabil (2016) 0.75
Distribution of body mass index among subjects with COPD in the Middle East and North Africa region: data from the BREATHE study. Int J Chron Obstruct Pulmon Dis (2015) 0.75
All-cause mortality in asthma. The importance of age, comorbidity, and socioeconomic status. Ann Am Thorac Soc (2014) 0.75
COPD Assessment Test (CAT) score as a predictor of major depression among subjects with chronic obstructive pulmonary disease and mild hypoxemia: a case-control study. BMC Pulm Med (2014) 0.75
Clinical factors and comorbidities affecting the cost of hospital-treated COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Determinants of chronic obstructive pulmonary disease severity in the late-elderly differ from those in younger patients. BMC Res Notes (2016) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
A measure of quality of life for clinical trials in chronic lung disease. Thorax (1987) 10.87
Development and first validation of the COPD Assessment Test. Eur Respir J (2009) 8.06
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 7.67
Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol (1998) 4.94
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol (2004) 2.88
Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J (2011) 2.38
Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest (2012) 2.34
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Comparison of endoscopic findings with symptom assessment systems (FSSG and QUEST) for gastroesophageal reflux disease in Japanese centres. J Gastroenterol Hepatol (2009) 2.05
Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 2.01
Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med (2008) 1.90
COPD and osteoporosis. Chest (2002) 1.60
Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.59
Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD (2012) 1.55
The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax (2011) 1.54
Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax (2008) 1.51
Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest (2001) 1.40
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respir Med (2013) 1.12
Impact of comorbidities on COPD-specific health-related quality of life. Respir Med (2012) 1.09
Validity of the COPD assessment test translated into local languages for Asian patients. Chest (2013) 0.94
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature (2009) 14.59
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Prediction of progression of coronary artery disease and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: the PREDICTION Study. Circulation (2012) 3.53
Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.09
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03
Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med (2004) 2.86
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax (2010) 2.86
Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.81
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest (2007) 2.67
Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med (2004) 2.50
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation (2010) 2.45
Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest (2003) 2.44
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med (2012) 2.27
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Global changes in the nuclear positioning of genes and intra- and interdomain genomic interactions that orchestrate B cell fate. Nat Immunol (2012) 2.16
Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest (2014) 2.15
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med (2010) 2.09
Variability of a closed, rebreathing setup for multiple breath wash-out testing in children. Pediatr Pulmonol (2012) 2.03
Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood (2004) 2.01
Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration (2012) 1.99
Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm (2011) 1.93
Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2008) 1.83
Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol (2003) 1.82
Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol (2009) 1.79
The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol (2009) 1.71
Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol (2011) 1.69
Angioplasty for chronic total occlusion by using tapered-tip guidewires. Catheter Cardiovasc Interv (2003) 1.68
The effect of helium and oxygen on exercise performance in chronic obstructive pulmonary disease: a randomized crossover trial. Am J Respir Crit Care Med (2006) 1.65
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax (2007) 1.61
Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest (2003) 1.58
Predictors of osteoporosis and vertebral fractures in patients presenting with moderate-to-severe chronic obstructive lung disease. COPD (2012) 1.55
The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax (2011) 1.54
Apoptosis and epithelial injury in the lungs. Proc Am Thorac Soc (2005) 1.53
Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res (2009) 1.51
The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. J Bronchology Interv Pulmonol (2014) 1.51
Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res (2011) 1.51
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol (2010) 1.51
The role of apoptosis in acute lung injury. Crit Care Med (2003) 1.43
Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med (2006) 1.42
Combination therapy of 15-epi-lipoxin A4 with antibiotics protects mice from Escherichia coli-induced sepsis*. Crit Care Med (2014) 1.42
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res (2013) 1.40
Long-term outcome of acute myocardial infarction patients treated with stents versus balloon angioplasty: results from randomized trials. Int J Cardiol (2008) 1.37
Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am J Respir Cell Mol Biol (2005) 1.35
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med (2010) 1.33
Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol (2008) 1.32
Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2002) 1.29
Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells. Am J Respir Cell Mol Biol (2008) 1.25
Cardiovascular events in patients with COPD: TORCH study results. Thorax (2010) 1.25
Epilysin (MMP-28) restrains early macrophage recruitment in Pseudomonas aeruginosa pneumonia. J Immunol (2009) 1.25
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health (2010) 1.21
Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol (2009) 1.21
Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology (2006) 1.18
TCDD treatment eliminates the long-term reconstitution activity of hematopoietic stem cells. Toxicol Sci (2003) 1.18
The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med (2010) 1.16
Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med (2014) 1.14
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Enhancement of the endotoxin recognition pathway by ventilation with a large tidal volume in rabbits. Am J Physiol Lung Cell Mol Physiol (2003) 1.13
Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J Pharmacol Exp Ther (2004) 1.12
Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis. J Clin Invest (2009) 1.12
Molecular and functional properties of lung SP cells. Am J Physiol Lung Cell Mol Physiol (2006) 1.12
The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis (2006) 1.11
Noise, artifact, and oversensing related inappropriate ICD shock evaluation: ALTITUDE noise study. Pacing Clin Electrophysiol (2012) 1.09
The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation. COPD (2012) 1.09
Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun (2013) 1.09
Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J (2012) 1.09
Effect of CD14 blockade on endotoxin-induced acute lung injury in mice. Am J Respir Cell Mol Biol (2003) 1.07
Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations? COPD (2012) 1.06
Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. Inhal Toxicol (2008) 1.06
Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol (2012) 1.06
Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA (2002) 1.05
Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2004) 1.05
Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol (2012) 1.04
Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest (2010) 1.04
Comparative study on transradial approach vs. transfemoral approach in primary stent implantation for patients with acute myocardial infarction: results of the test for myocardial infarction by prospective unicenter randomization for access sites (TEMPURA) trial. Catheter Cardiovasc Interv (2003) 1.04
Derivation of normative data for the COPD assessment test (CAT). Respir Res (2014) 1.02
Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol Med Rep (2013) 1.02
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem (2009) 1.02
Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. Chest (2013) 1.02
Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice. Am J Physiol Lung Cell Mol Physiol (2009) 1.01
Cigarette smoke induces nucleic-acid oxidation in lung fibroblasts. Am J Respir Cell Mol Biol (2009) 1.01
DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One (2013) 1.00